By targeting the IFN‐γ‐STAT1 axis, NGO suppresses M1‐mediated inflammation while simultaneously enhancing Treg induction, and reducing GVHD severity without compromising essential immune functions. The gene discussed is STAT1; the disease is graft versus host disease.